Impact Therap-b (7630.HK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 33 | 5 | 5 | 2 | - |
| Operating profit | $m | -32 | -4 | ||||||
| Net profit | $m | - | - | - | 1 | -36 | -41 | -5 | - |
| EPS reported | $ | -0.15 | -0.02 | ||||||
| Operating cashflow per share | $ | -0.05 | -0.05 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.05 | -0.05 | ||||||
| Free cash flow | $m | -14 | -14 | ||||||
| Net debt | $m | 86 | -156 | ||||||
| Book value equity | $m | -137 | 114 | ||||||
| Book value per share | $ | -0.50 | 0.40 | ||||||
| Number of shares | m | 276.17 | 282.46 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -10.84 | 12.99 | ||||||
| P/S LTM | x | 278.67 | 679.30 | ||||||
| P/FCF LTM | x | -109.45 | -104.86 | ||||||
| EV/EBITDA LTM | x | -50.02 | -422.98 | ||||||
| EV/Sales LTM | x | 294.87 | 25.01 | ||||||
| Earnings Yield LTM | % | -2.78% | -6.54% | ||||||
| FCF Yield | % | -0.91% | -0.95% | ||||||
| Quality | |||||||||
| ROE | % | +30.08% | +323.05% | ||||||
| ROIC | % | -95.95% | -19.89% | ||||||
| Operating margin | % | -6.01% | -1.74% | ||||||
| Gross margin | % | +84.20% | +87.17% | ||||||
| FCF/Sales | % | -254.61% | -82.60% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +13.86% | -53.29% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.11 | -22.72 | ||||||
| Net Debt/EBITDA | x | -2.75 | 4.13 | ||||||
| EBIT/Net interest | x | -3.35 | -3.51 | ||||||
| Net debt/market cap | % | +8.29% | +0.09% | ||||||
| Net debt/Equity | x | -0.63 | -1.37 | ||||||
| Gross debt/equity | x | -0.90 | 0.01 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Similar companies
- Tong Ren Tang Technologies Co. Ltd.
- Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
- Senores Pharmaceuticals Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
- SMS Pharmaceuticals Limited
- Zhejiang Zhenyuan Share Co., Ltd.
- Hubei Guangji Pharmaceutical Co., Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
- Tong Ren Tang Technologies Co. Ltd.
- Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
- Senores Pharmaceuticals Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
- SMS Pharmaceuticals Limited
- Zhejiang Zhenyuan Share Co., Ltd.
- Hubei Guangji Pharmaceutical Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free